Welcome To KAYA17
Medical Diagnostics at Its Best
KAYA17 is at the leading edge in the evolution of medical diagnostics. Traditionally, all medical diagnostics were based upon obtaining a sample from a patient, sending it to a remote lab and waiting several hours (more typically, a day or two) for the results to arrive.
NOT ANY MORE!
New technology has enabled results to be obtained on the spot within 30 minutes. However, these Point-of-Care Tests have one problem. They are not as accurate as the laboratory tests done in remote labs.
Now, using KAYA17’s novel test platform, the results can be obtained in as little as 15 minutes! And in terms of accuracy, our results correspond totally with laboratory tests.
Our first product, an on-the-spot POCT for COVID-19, achieves what was earlier deemed an unattainable goal – a test which is BOTH Rapid and Accurate. Novel POCTs for other medical conditions are under development.
What Makes KAYA17 Unique
The KAYA17 POCT Benefits and Potential
The KAYA17 point-of-care test is a 15-minute Rapid test for COVID-19, which is perfectly adaptable for testing individuals, as well as small or large groups of people. The testing may be done infrequently or on a regular periodic basis. It can also be done quickly, accurately, and inexpensively. KAYA17’s proprietary software makes the workflow, and the initial data gathering to electronic delivery of the final results simple in various testing scenarios.
Testing at Airports, Terminals and Stations
Rapid, accurate, inexpensive testing will save the industry billions.
Testing at Schools and Institutions
A saliva sample is convenient. A nasal swab is not, especially for the elderly and children.
Testing at Workspaces and Factories
KAYA17 is the only rapid test in the world that is also viable for pooling, hugely reducing costs.
Equivalence With RT-PCR
KAYA17 results are in accord with results from gold standard RT-PCR machines
Quick Group Testing
Organized workflow and software enables 20 tests/hour/instrument
FDA (EUA) Expected, Sale Through CLIA Labs Permitted
Clinical trials (saliva, nasal swab) and validation successfully completed. Emergency Use Authorisation by FDA is anticipated. Current published FDA Policy permits sale of KAYA17 products through CLIA Labs.